150 results about "Colon tissue" patented technology

The invention discloses bifidobacterium longum and the application thereof and belongs to the technical field of biologics. The invention provides a bifidobacterium longum YS108R strain which has thecharacteristic of generating viscous exopolysaccharide, and has a remarkable improvement function on DSS (Dextran Sulfate Sodium) induced mouse colitis models. The strain has a relatively good capability of enduring simulated gastrointestinal fluids, is capable of remarkably reducing disease activity indexes of mice in the DSS induction period, and has an effective protection function on colon tissue. In addition, the bifidobacterium longum YS108R disclosed by the invention is separated from intestinal florae of healthy people, is free of toxic and/or side effects on human bodies, and has certain advantages when being compared with conventional medicine treatment. The strain can be used for preparing probiotic powder, fermented milk, and the like, and has wide market prospects.

Differential gene expression associated with histopathologic features of colorectal disease can be performed with nucleic acid arrays. Such arrays can comprise a pool of polynucleotide sequences from colon tissues, and the detection of the overexpression or underexpression of polynucleotide sequences (or subsequences or complements thereof) from this pool can provide information relating to the detection, diagnosis, stage, classification, monitoring, prediction, prevention or treatment of colorectal disease.

There is disclosed the cloning and identification of human IL-23R splice variants caused by alternative splicing of the IL-23R mRNA in human. Alternative mRNA forms occur through skipping one, multiple full exons or partial exons, within the IL-23R gene. A total of twenty-five (25) different IL-23R transcripts were identified. A novel exon deletion (exon 9) isoform in the interleukin 23 receptor is disclosed, denoted as Δ9. The present application also describes a quantitative assay to measure different IL-23R isoform. Detection of Δ9 isoform of IL-23R is predominantly present in colon and cervical tissues. A decrease in Δ9 is observed in inflamed colon tissues in Crohn's patients. There is disclosed a method of predicting Crohn's disease by measuring Δ9 isoform of IL-23R.

The present invention provides lactobacillus reuteri for preventing ulcerative colitis. The strain is named as lactobacillus reuteri RAM0101 and deposited on May 27, 2019 at China General Microbiological Culture Collection Center and has a preservation number of CGMCC NO.17853. C57BL/6N mice are used as test objects, dextran sodium sulfate (DSS) is used to induce the mice to form an ulcerative colitis model and the model is also used to investigate effectiveness of the strain in preventing the ulcerative colitis. The lactobacillus reuteri can relieve weight loss, diarrhea, hematochezia and disease activity index (DAI) score of the ulcerative colitis mice induced by the DSS, protects pathological damages of colon tissues of the mice induced by the DSS, can enhance colon tissue epithelial barrier completeness and is also free of toxin and harms.

A method for processing CT colonography input image voxel data representative of 3-dimensional images of a colon having gas and stool tagged with stool tagging agent, to remove the stool from the images. The input image voxel data is generated by an imaging instrument having a characteristic point spread function representative of instrument blurring. The point spread function of the instrument can be empirically determined, and the image data processed as a function of the point spread function to accurately identify and remove the tagged stool. In one embodiment of the invention, portions of the image data representative of the tagged stool and colon tissue are dilated as a function of the point spread function. In another embodiment, portions of the image data representative of the tagged stool are convolved with the point spread function to determine the fractional amount of stool present in the image portions, and the tagged stool subtracted by reducing the intensities of the associated portions of the image by an amount proportional to the fractional amount of stool present.

The invention presents methods of using Fourier transform infrared microspectroscopy (FTIR-MSP) for distinguishing between normal and abnormal human cells and for diagnosis and digital staging of human cells on biopsied samples. The invention further presents computational methods employing neural network (NN) based classifiers for diagnosis and digital staging of adenomatous polyp and malignant tissue types of biopsied samples of human cells.

The invention relates to the technical field of pharmaceuticals, and more particularly to application of a propolis ethanol extract in preparation of medicaments, food and health care products for prevention or treatment of inflammatory bowel diseases. The propolis ethanol extract is obtained by extraction by using 80 to 95% ethanol as a solvent. Research findings show that the propolis ethanol extract can inhibit the health state of a body during the development course of ulcerative colitis, reduce the shortening of the length of the colon, and improve the pathological structure of a colon tissue; therefore, the propolis ethanol extract can be applied to development of medicaments, health care products and food for prevention or treatment of the ulcerative colitis.

The invention provides application of METRNL protein as a protein molecule marker for detecting colon cancer and application of the METRNL protein in preparing a colon cancer diagnostic reagent or a kit. Immunohistochemistry is carried out on 30 pairs of human colon cancer tissues and para-carcinoma tissues through immunohistochemistry tests, and the result proves that the METRNL protein has differential expression in cancer tissues and para-carcinoma tissues of the human colon cancer. Therefore, whether a patient has the colon cancer can be detected according to the expression quantity of the METRNL protein in colon tissues.

The invention discloses bifidobacterium longum subsp.infantis for relieving colitis and application, and belongs to the technical field of biology. The bifidobacterium longum subsp. Infantis CCFM1210 provided by the invention has the immunoregulation capability, and can improve the intestinal barrier and relieve colitis. Animal experiments prove that through intervention of the bifidobacterium longum subsp.infantis CCFM1210, tissue damage of a mouse can be remarkably relieved, the myeloperoxidase level can be remarkably reduced, the content of tight junction protein in colon tissue can be remarkably increased, the levels of proinflammatory cytokines IL-1beta and IL-6 can be remarkably reduced, and the level of an anti-inflammatory cytokine IL-10 can be remarkably increased; the concentration of butyric acid is obviously increased, the diversity of intestinal flora is obviously improved, and the disorder of the flora is relieved. Compared with a traditional medicine for treating colitis, a medicine or a probiotic preparation prepared from the bifidobacterium longum subsp. Infantis CCFM1210 disclosed by the invention has certain advantages and has a wide market prospect.

The invention discloses application of oxyberberine in preparation of a medicament for treating ulcerative colitis. The research of the invention finds that: the oxyberberine can safely and effectively resist ulcerative colitis, and comprises the following effects: remarkably improving general symptoms of ulcerative colitis mice, improving pathological injury, reducing the level of colon tissue inflammatory cytokines and immunoglobulins in serum, and increasing expression of tight junction proteins (TJs) in colon tissues. The drug effect of the oxyberberine for preventing and treating the ulcerative colitis is equivalent to that of azathiopurine of a traditional first-line treatment drug, and is superior to that of berberine. In addition, the oxyberberine has high safety, and the daily application dosage of the oxyberberine is not strictly limited in terms of safety and can be adjusted according to clinical actual conditions during use, so that better curative effect is ensured. The invention provides a better new drug choice for clinically treating ulcerative colitis, and the oxyberberine has good application prospect for clinical treatment of ulcerative colitis.

The invention discloses lactobacillus rumen for relieving colitis and application, and belongs to the technical field of biology. The invention provides a strain of lactobacillus rumen CCFM1141. The strain has immunoregulation ability, can improve intestinal barrier and relieve colitis, and can significantly reduce disease activity index of mice during DSS induced colitis period. Compared with mice in a model group, tissue damage of mice in an intervention group of the lactobacillus rumen CCFM1141 is remarkably reduced, proinflammatory cytokines IL-1beta and IL-17 in colon tissues are remarkably reduced, and the concentrations of acetic acid, propionic acid and butyric acid are remarkably increased. The medicine prepared by adopting the lactobacillus rumen CCFM1141 provided by the invention has certain advantages compared with the traditional medicine for treating colitis, and the strain can be used for preparing probiotic preparations and the like, and has a wide market prospect.

The invention relates to the technical field of medicines, in particular to clinical application of a compound enema consisting of resina draconis and common bletilla tuber to treating ulcerative colitis. Experiments of a DNCB (dinitrochlorobenzene) induced rat ulcerative colitis animal model and pathology observation, and the like find that the compound resina draconis enema can effectively improve rat diarrhea, hematochezia, weight reduction and colon tissue pathomorphology change and regulate phlogistic or phlogistic-inhibiting immunological factors, and facilitates to inflammation elimination and tissue recovery. 83 chronic nonspecific ulcerative colitis (UC) patients are treated by adopting the compound enema, which finds that the compound resina draconis enema can improve various hemarheology indexes of blood plasma viscosity, hematocrit, fibrinogen, and the like of the UC patient, and shows that the compound resina draconis enema has satisfied treatment effect on the UC, does not contain hormone and sulfanilamides, has no remarkable bad effects and is worthy of being clinically popularized and applied.

The present invention discloses novel nucleic acid sequences which are implicated in the growth regulation of the epithelial cells of the colon, and which sequences are differentially expressed in cancerous colon tissues compared to normal colon tissues. These sequences are useful in diagnosing abnormal cell growth, treatment of abnormal cell growth and screening assays for, treatments of abnormal cell growth.

The present invention relates to medicine technology, and is the new use of water extract of acalypha copperleaf as a kind of euphorbiaceae plant in preparing medicine for treating chronic ulcer colonitis. Animal test shows that water extract of acalypha copperleaf can improve effectively the symptoms, including diarrhea, hemafecia, losing weight, colon tissue form change, etc. of ulcer colonitits rat model; and can eliminate neutral granulocyte. Biochemical detection and molecular biological test proves its antioxidant and anti-NO free radical effect, and the function of inhibiting the expression of inducing NO syntase in the RNA level. Therefore, water extract of acalypha copperleaf may be used in preparing medicine for treating chronic ulcer colonitis.

The invention relates to an application of Chinese traditional herb monomer wedelolactone as a drug for treating ulcerative colitis. According to the application, wedelolactone is obtained from Chinese traditional herb material eclipta, and the structure of wedelolactone is determined according to spectrum data. Through intragastric administration of wedelolactone, the body weight change of a model mouse is obviously changed, the length of the colon is increased, the inflammation level of the colon is obviously hanged, the NO content reflecting the inflammation degree of the colon is reduced, the activity of myeloperoxidase (MPO) in the colon tissue is reduced, release of inflammatory factors IL-8 of Caco-2 cells excited byIL-1beta is inhibited in vitro. The results of in-vivo and in-vitro experiments show that wedelolactone under certain dosage can obviously inhibit release of the inflammatory factors of the colon tissue, so that the acute ulcerative colitis of the mouse caused by dextran sulphate sodium salt (DSS) can be obviously improved, and therefore, wedelolactone has a novel application as a drug for treating or improving ulcerative colitis.

The invention discloses bifidobacterium bifidum for relieving constipation as well as a fermented food and a probiotic preparation prepared from the bifidobacterium bifidum, and belongs to the technical field of microorganisms. The Bifidobacterium bifidum CCFM1167 provided by the invention can be used for effectively relieving the first black stool time, the intestinal tract propulsion rate and the water content of stool of a mouse with constipation, and has the effect of obviously improving the apparent pathological indexes of constipation; in the detection of physicochemical indexes, the bifidobacterium bifidum can also influence the content of gastrointestinal active peptides, so that the intestinal peristalsis is influenced; the bifidobacterium bifidum also can effectively relieve pathological injury of colon tissues so as to effectively relieve constipation symptoms, and compared with bifidobacterium longum GDMCC NO: 60941, the bifidobacterium bifidum has more obvious influence on MTL content, further has more obvious effect on increasing the small intestine propulsion rate, and is more suitable for constipation patients with weak small intestine propulsion.

In vi tro methods of determining whether or not an individual has metastasized colorectal cancer cells are disclosed. In vitro methods of determining whether or not tumor cells are colorectal in origin are disclosed. In vitro kits for practicing the methods of the invention and to reagents and compositions useful to practice the methods, for example as components in such in vitro kits of the invention are provided. Methods of and kits and compositions for analyzing tissue samples from the colon tissue to evaluate the extent of metastasis of colorectal tumor cells are disclosed.

The invention discloses a bifidobacterium bifidum capable of reducing colon pathological injury and relieving constipation, and belongs to the field of microorganisms. The bifidobacterium bifidum CCFM1165 provided by the invention can effectively improve the first black stool time, the intestinal tract propulsion rate, the stool water content and the pathological damage of colon tissues of a constipation mouse. The strain provided by the invention can influence the content of excitement type and inhibition type gastrointestinal active peptides, and mainly increases the content of two short-chain fatty acids, so that the constipation symptom is relieved. Meanwhile, the bifidobacterium bifidum can effectively increase the abundance of bifidobacteria in excrement and can also relieve pathological damage of colon tissue, so that the effect of comprehensively relieving constipation diseases is achieved. In addition, compared with GDMCC NO.60939, the content of MTL in serum is better increased, secretion of 5-HT in colon tissue is promoted, and the propelling effect on small intestine peristalsis is more remarkable, so the GDMCC NO.60939 can be applied to disease control in a more targeted mode.

The invention relates to a weakly supervised gland instance segmentation method based on point labeling. The method comprises the following steps: acquiring a colon histopathology image; carrying outpoint labeling on gland instances existing in the image to generate a gland point detection training sample set; establishing a gland point detection model; performing deep learning training on the gland point detection model by using the gland point detection training sample set; predicting a high confidence point in the colon histopathology image by using the gland point detection model after deep learning training, and generating a gland instance segmentation training sample set; establishing a gland instance segmentation model; performing deep learning training on the gland instance segmentation model by using the gland instance segmentation training sample set; and using the gland instance segmentation model after deep learning training to segment the gland instance of the colon histopathology image. According to the method, automatic segmentation of the gland instance in the colon histopathology image is realized, and the data annotation cost of artificial segmentation of the gland in colon cancer diagnosis is reduced.

The invention belongs to the technical field of biological medicine, and particularly relates to a polypeptide fragment D and application thereof. The polypeptide fragment D has an amino acid sequence shown as SEQ ID No.1, the ninth amino acid Xaa is Tyr, Val, Gly, Ser, Gln or absent, the twentieth amino acid Xaa is Ser, Gln, Glu, Tyr, Arg or absent, and the 25th amino acid Xaa isAsn, Thr, Ser, Pro, Leu or absent. The MP-D significantly improves the colon pathological form of an IBD mouse model, reduces the colon histopathology score and the colon interferon-gamma expression content, and has the ability to intervene in the occurrence of inflammatory bowel disease in mice.